1. Home
  2. QURE vs ATLC Comparison

QURE vs ATLC Comparison

Compare QURE & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QURE
  • ATLC
  • Stock Information
  • Founded
  • QURE 1998
  • ATLC 1996
  • Country
  • QURE Netherlands
  • ATLC United States
  • Employees
  • QURE N/A
  • ATLC N/A
  • Industry
  • QURE Biotechnology: Pharmaceutical Preparations
  • ATLC Finance: Consumer Services
  • Sector
  • QURE Health Care
  • ATLC Finance
  • Exchange
  • QURE Nasdaq
  • ATLC Nasdaq
  • Market Cap
  • QURE 725.4M
  • ATLC 766.4M
  • IPO Year
  • QURE 2007
  • ATLC 1999
  • Fundamental
  • Price
  • QURE $14.28
  • ATLC $56.91
  • Analyst Decision
  • QURE Strong Buy
  • ATLC Strong Buy
  • Analyst Count
  • QURE 10
  • ATLC 5
  • Target Price
  • QURE $37.20
  • ATLC $62.00
  • AVG Volume (30 Days)
  • QURE 1.2M
  • ATLC 64.8K
  • Earning Date
  • QURE 07-31-2025
  • ATLC 08-07-2025
  • Dividend Yield
  • QURE N/A
  • ATLC N/A
  • EPS Growth
  • QURE N/A
  • ATLC 21.75
  • EPS
  • QURE N/A
  • ATLC 5.17
  • Revenue
  • QURE $20,201,000.00
  • ATLC $424,877,000.00
  • Revenue This Year
  • QURE N/A
  • ATLC $273.30
  • Revenue Next Year
  • QURE $278.91
  • ATLC $11.92
  • P/E Ratio
  • QURE N/A
  • ATLC $10.71
  • Revenue Growth
  • QURE 6.30
  • ATLC 17.71
  • 52 Week Low
  • QURE $3.73
  • ATLC $25.44
  • 52 Week High
  • QURE $19.18
  • ATLC $64.70
  • Technical
  • Relative Strength Index (RSI)
  • QURE 47.07
  • ATLC 66.24
  • Support Level
  • QURE $13.65
  • ATLC $50.34
  • Resistance Level
  • QURE $14.46
  • ATLC $52.03
  • Average True Range (ATR)
  • QURE 0.78
  • ATLC 1.84
  • MACD
  • QURE -0.18
  • ATLC 0.66
  • Stochastic Oscillator
  • QURE 27.21
  • ATLC 96.53

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

About ATLC Atlanticus Holdings Corporation

Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.

Share on Social Networks: